» Articles » PMID: 11598248

Selection of Patients for Resection of Hepatic Metastases: Improved Detection of Extrahepatic Disease with FDG Pet

Overview
Journal Radiographics
Specialty Radiology
Date 2001 Oct 13
PMID 11598248
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

A rapidly emerging clinical application of positron emission tomography (PET) is the detection of tumor tissue at whole-body studies performed with the glucose analogue 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG). High rates of recurrence after partial hepatic resection in patients with colorectal cancer liver metastases indicate that current presurgical imaging strategies are failing to show extrahepatic tumor deposits. Although FDG PET cannot match the anatomic resolution of conventional imaging techniques in the liver and the lungs, it is particularly useful for identification and characterization of extrahepatic disease. FDG PET can show foci of metastatic disease that may not be apparent at conventional anatomic imaging and can aid in the characterization of indeterminate soft-tissue masses. Several sources of benign and physiologic increased activity at FDG PET emphasize the need for careful correlation with findings of other imaging studies and clinical findings. FDG PET can improve the selection of patients for partial hepatic resection and thereby reduce the morbidity and mortality associated with inappropriate surgery.

Citing Articles

PET-CT in Clinical Adult Oncology: III. Gastrointestinal Malignancies.

Koppula B, Fine G, Salem A, Covington M, Wiggins R, Hoffman J Cancers (Basel). 2022; 14(11).

PMID: 35681647 PMC: 9179927. DOI: 10.3390/cancers14112668.


Comparison of MRI and 18F-FDG PET/CT in the Liver Metastases of Gastrointestinal and Pancreaticobiliary Tumors.

Tahtabasi M, Erturk S, Basak M Sisli Etfal Hastan Tıp Bul. 2021; 55(1):12-17.

PMID: 33935530 PMC: 8085444. DOI: 10.14744/SEMB.2020.80270.


Defining the Modalities of Intravenous Contrast Application During the Diagnostics of Hepatic Metastases with Computerized Tomography.

Kutllovci A, Ymeri H, Zogaj D, Kutllovci S, Zogaj D Acta Inform Med. 2016; 24(1):25-9.

PMID: 27041807 PMC: 4789622. DOI: 10.5455/aim.2016.24.25-29.


Selective Use of (18)F-Fluorodeoxyglucose-Positron Emission Tomography and Computed Tomography in the Management of Metastatic Disease from Colorectal Cancer: Results from a regional centre.

Jafferbhoy S, Chambers A, Mander J, Paterson H Sultan Qaboos Univ Med J. 2015; 15(1):e52-7.

PMID: 25685386 PMC: 4318607.


The role of positron emission tomography in colorectal carcinoma.

Nachar O Ochsner J. 2012; 4(3):146-55.

PMID: 22822338 PMC: 3399273.